Target intelligence / Profile preview

Cyclin-dependent kinase 5 activator 1 (CDK5R1)

Target
CDK5R1
Molecular classification
Enzyme regulator (protein cofactor/subunit required for enzymatic activity), Cyclin-dependent kinase regulatory subunit, Other (neuron-specific kinase activator)
01

Overview

Cyclin-dependent kinase 5 activator 1 (CDK5R1, also known as p35) is a neuron-specific regulatory subunit essential for the activation of cyclin-dependent kinase 5 (CDK5), a serine/threonine kinase critical for central nervous system development and function[1][3]. The p35 protein is cleaved by calpain to generate p25, a form that results in deregulated CDK5 activity and is implicated in neurodegenerative pathology; in particular, accumulation of p25 correlates with increased CDK5 activity and the hyperphosphorylation of tau protein observed in Alzheimer’s disease[1]. CDK5R1 is thus a key modulator of neuronal migration, synaptic plasticity, and has a central role in several brain diseases, mainly neurodegeneration and neurodevelopmental disorders[1][3].

Other names
Cyclin-dependent kinase 5 regulatory subunit 1CDK5 activator 1p35p25p23p35nck5aNCK5ACDK5Rtau protein kinase II 23 kDa subunitTPKII regulatory subunitneuronal CDK5 activatorregulatory partner for CDK5 kinase
02

Mechanism of action

For drugs targeting this pathway (e.g. CDK5 inhibitors): inhibition of CDK5 kinase activity by blocking either the kinase itself or interfering with its interaction with activators like p35/p25[3][1].

03

Biological functions

Central nervous system developmentNeuron-specific activator of CDK5Regulation of neuronal migration and differentiationRegulation of cell cycle in neuronsModulation of synaptic plasticity, neurite outgrowth, and dendritic spine morphogenesisRegulation of phosphorylation of key neuronal substrates (e.g., tau protein, amyloid precursor protein)
04

Disease associations

Neurodegenerative disease (notably Alzheimer’s disease)Neurodevelopmental disorders (e.g., autism spectrum disorder, intellectual disability)Potential roles in cancer and other CNS pathologies
05

Safety considerations

Direct targeting of CDK5R1 or modulation of p35/p25 levels could disrupt essential neuronal development and function, potentially leading to severe CNS side effects, cognitive impairment, or developmental defects[1][3].
06

Interacting drugs

No approved small molecules directly targeting CDK5R1 (p35/p25) itself as drug, but indirect targeting via CDK5 inhibitors is under investigation (e.g., roscovitine/seliciclib as a CDK5 inhibitor, not specific for the regulatory subunit)[3].
07

Biomarkers

Accumulation of p25 (the cleaved form of p35) is a proposed biomarker for neurodegeneration, especially in Alzheimer’s disease[1][3].

Beyond the preview

Go deeper on Cyclin-dependent kinase 5 activator 1 (CDK5R1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cyclin-dependent kinase 5 activator 1 (CDK5R1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call